Analyst Research Report Snapshot


Dainippon Sumitomo Pharma Co., Ltd.




MarketLine (a Datamonitor Company)


08 Apr 2014





Companies referenced:


Available for Immediate Download

Dainippon Sumitomo Pharma Co., Ltd. - SWOT, Strategy and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings, detailed financials, and corporate actions, providing a 360° view of the company. Features: - Detailed information on Dainippon Sumitomo Pharma Co., Ltd. required for business and competitor intelligence needs - A study of the major internal and external factors affecting Dainippon Sumitomo Pharma Co., Ltd. in the form of a SWOT analysis - An in-depth view of the business model of Dainippon Sumitomo Pharma Co., Ltd. including a breakdown and examination of key business segments - Five-year financial information and charts, including balance sheet, income statement, cash flows, market capitalization and multiples, and key ratios for Dainippon Sumitomo Pharma Co., Ltd. - Intelligence on Dainippon Sumitomo Pharma Co., Ltd.nv’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors - News about Dainippon Sumitomo Pharma Co., Ltd., such as business expansion, restructuring, and contract wins - Large number of easy-to-grasp charts and graphs that present important data and key trends Highlights: Dainippon Sumitomo Pharma (DSP or ‘the group’) is a Japan-based global provider of pharmaceutical products. It is a subsidiary of Sumitomo Chemical. The group primarily operates in Asia and North America. It is headquartered in Osaka, Japan, and employed 7,601 people as of March 31, 2012. The group recorded revenues of JPY350,396 million ($4,450 million*) during the financial year ended March 2012 (FY2012), a decrease of 7.7% compared with FY2011. The operating profit of the group was JPY20,402 million ($259.1 million*) during FY2012, a decrease of 34.1% compared with FY2011. The net profit was JPY8,630 million ($109.6 million*) in FY2012, a decrease of 48.6% compared with FY2011. *Calculated using a constant conversion rate of JPY1 = $0.0127 for the financial year ended March 31, 2012. Reasons to Purchase: - Gain understanding of Dainippon Sumitomo Pharma Co., Ltd. and the factors that influence its strategies - Track strategic initiatives of the company and latest corporate news and actions - Assess Dainippon Sumitomo Pharma Co., Ltd. as a prospective partner, vendor or supplier - Support sales activities by understanding your customers' businesses better - Stay up to date on Dainippon Sumitomo Pharma Co., Ltd.’s business structure, strategy and prospects

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.